Pancreatic cancer is a uniformly lethal disease because most patients have no symptoms until the cancer has spread and become inoperable. Moreover, once the cancer has formed, chemotherapy offers only minimal improvement in survival. Cancers that are 2 cm or smaller have a much better survival outcome than those that are larger. We propose to develop a serum based early detection test for pancreatic cancer. Nearly all serum cancer biomarker tests are based on the detection of proteins. Therefore, we will use proteomics technology to identify the proteins that are specific to pancreatic cancer and pre-cancer. Our preliminary data is exciting: 1) we have already identified and quantified 656 proteins in pancreatic cancer tissue, of which 90 proteins were up-regulated and 61 were down-regulated in cancer by at least a 2-fold change. 2) Validation studies to date suggest that the proteomics measurements are robust and accurate. The proteins have been analyzed with regard to function, nearly one quarter are extracellular/membrane proteins- thus excellent candidates for pancreatic cancer biomarker development (membrane proteins are shed into the blood). 3) Two of the discovered protein biomarkers, Annexin II and Integrin B1, have been further investigated; both of these proteins have marked over-expression in cancer cells, but not in normal pancreatic ducts or in non-ductal pancreatic cells when evaluated by tissue array and immunohistochemistry. 4) One of the proteins, Galectin 1, has been validated by western blotting and then developed into an ELISA. Galectin 1 could distinguish pancreatic cancer versus normal sera with 100% accuracy in preliminary testing. 5) We have developed a MALDI-TOF-TOF methodology for measuring proteins directly from serum, so that ELISA's would eventually not be necessary for biomarker detection. In this proposal, we describe our methods for the comprehensive development of candidate pancreatic cancer biomarkers and the algorithm that will be used to determine which biomarkers are best suited for development into a clinically useable test. The studies proposed here have the potential to significantly change the outcome in a disease that has made minimal headway in the past 100 years. The use of proteomics technology has enormous potential. Our proposed studies can lead to: earlier diagnosis- improving the prognosis of this deadly disease; better understanding of tumorigenesis in pancreatic cancer; targeted proteins for future therapeutic interventions including new drug/vaccine development; development of disease response markers. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA107209-01A2
Application #
7102545
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Kagan, Jacob
Project Start
2006-09-22
Project End
2011-07-31
Budget Start
2006-09-22
Budget End
2007-07-31
Support Year
1
Fiscal Year
2006
Total Cost
$525,997
Indirect Cost
Name
University of Washington
Department
Pathology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Pan, Sheng; Chen, Ru; Tamura, Yasuko et al. (2014) Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma. J Proteome Res 13:1293-306
Foygel, Kira; Wang, Huaijun; Machtaler, Steven et al. (2013) Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. Gastroenterology 145:885-894.e3
Pan, Sheng; Brentnall, Teresa A; Kelly, Kimberly et al. (2013) Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges. Proteomics 13:710-21
Chen, Ru; Pan, Sheng; Ottenhof, Niki A et al. (2012) Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol Ther 13:899-907
Pan, Sheng; Chen, Ru; Brand, Randall E et al. (2012) Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res 11:1937-48
Pan, Sheng; Tamura, Yasuko; Chen, Ru et al. (2012) Large-scale quantitative glycoproteomics analysis of site-specific glycosylation occupancy. Mol Biosyst 8:2850-6
Pan, Sheng; Chen, Ru; Stevens, Tyler et al. (2011) Proteomics portrait of archival lesions of chronic pancreatitis. PLoS One 6:e27574
Pan, Sheng; Chen, Ru; Aebersold, Ruedi et al. (2011) Mass spectrometry based glycoproteomics--from a proteomics perspective. Mol Cell Proteomics 10:R110.003251
Pan, Sheng; Chen, Ru; Crispin, David A et al. (2011) Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res 10:2359-76
Chen, Ru; Crispin, David A; Pan, Sheng et al. (2010) Pilot study of blood biomarker candidates for detection of pancreatic cancer. Pancreas 39:981-8

Showing the most recent 10 out of 17 publications